Former pharma executive who joined HHS to help lower drug

New Post Public Reply Private Reply Replies (1) Message Board
wowhappens28
189
Former pharma executive who joined HHS to help lower drug prices found bludgeoned to death in D.C. … ruled “suicide”

That is how hawks Deep State works, lovely people murder a man trying to lower drug prices and The Chief Medical Examiner’ covers it up

https://www.naturalnews.com/2018-11-18-former...icide.html

former executive for Pfizer, recently tasked with joining HHS to help reduce the prices of Big Pharma’s monopoly prescription medications, was found bludgeoned to death outside his Washington D.C. apartment. Local police ruled the death of Daniel Best a suicide, raising immediate questions about how an individual can bludgeon himself to death with multiple blows.

“The city’s Office of the Chief Medical Examiner on Thursday said Best died from “multiple blunt force injuries” and it ruled his death a suicide. It would not release further information,” reports Cleveland.com. The news website also reports:

In announcing his death, HHS Secretary Alex Azar said the 49-year-old former CVSHealth and Pfizer Pharmaceuticals executive agreed to work at HHS “out of a desire to serve the American people by making health care more affordable.”

Obviously a murder… and a cover-up
Not everybody is buying the official explanation. “The Chief Medical Examiner’s verdict raised questions among the health community, with many people refusing to believe Best killed himself by repeatedly hitting himself with a blunt object until he died,” reports NeoNettle.com.

NeoNettle also reports:

According to Washington, D.C. Police, Best was found “unresponsive” near the garage door exit of an apartment building in D.C.’s Navy Yard neighborhood at 5:25 a.m. on November 1, and was pronounced dead by medical personnel who responded to the scene.

To believe that Daniel Best murdered himself strains any shred of credibility. If a man wanted to kill himself, why would he attempt to do it with a blunt object requiring multiple strikes? And why would he choose to do it just outside the garage exit door of an apartment complex rather than inside his own living room?

Support our mission to keep you informed: Discover the extraordinary benefits of turmeric gummy bears and organic "turmeric gold" liquid extract, both laboratory tested for heavy metals, microbiology and safety. Naturally high in potent curcuminoids. Delicious formulations. All purchases support this website (as well as your good health). See availability here.

We must also consider who stands to benefit from interfering with a process that might end Big Pharma’s drug price monopoly. The corrupt pharmaceutical industry, which routinely bribes doctors, pushes fake science and uses human beings as guinea pigs for medical experiments, also murders children with toxic vaccines. (Over 100,000 U.S. children are maimed or killed by vaccines each year.) Why would they hesitate to kill one man who might stand in their way of continued ridiculous profits?

This is another big reason why all those who criticize Big Pharma should carry one or more concealed firearms (and be prepared to fire at multiple attackers as needed). Yes, the drug cartels literally have people murdered. I’ve been death-threated so many times, I’ve lost count…

Why Big Pharma is willing to murder people to protect its scandalous profit model
Big Pharma is a functioning drug cartel that enjoys anti-free market monopoly protections enforced by corrupt FDA and FTC regulators.

The purpose of the pharmaceutical industry’s entire existence is to extract the maximum amount of money from the U.S. economy by pretending to make sick people healthier through the widespread consumption of high-profit pharmaceutical medications. However, the profit model of the industry is almost entirely based on convincing healthy people they need lifelong medications to be healthy. This requires, of course, the “marketing of disease” that scares people into thinking they need drugs for completely normal physiological conditions (such as feeling depressed from time to time, which is a normal human experience).

The more medications people take, the sicker they become, requiring yet more secondary medications to “treat” the negative health symptoms caused by the primary medications. The real profit model of the pharmaceutical industry is to keep people sick, then charge them monopoly prices for dangerous medications that utterly fail to achieve any lasting improvement in health. Any effort to reduce drug prices or monopoly profits will be met with extreme resistance… and perhaps acts of murder funded by the industry itself.

The statin drug / cholesterol scam, all by itself, is a multi-decade long quack science medical scam that has extracted nearly half a trillion dollars from the world economy by pretending that cholesterol is a “disease.” In truth, statin drugs cause accelerated aging, brain damage, diabetes, extreme muscle fatigue and a long list of other serious health complications that demand further medication. That’s why statin drugs are known as gateway drugs that ultimately recruit lifelong patients to boost Big Pharma’s profits. There’s also zero evidence that statin drugs improve patient survival at all.

The entire sham is rooted in utterly faked science, ghost-written “science” papers, the bribery of regulatory officials and the incessant propaganda indoctrination of med schools with Big Pharma brainwashing materials. Statin-pushing quacks like Steven Nissen have been exposed for extreme conflicts of interest, drug “prostitution” and science denialism.

If you don’t realize that Big Pharma murders people to profit its profits, you have no idea what Big Pharma really is. Their entire business model is based on human suffering, exploitation and death.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

Updated Category News Views 2

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Continue Reading
SCO at 25: China's Strategic Push for Regional Growth

Updated Category News Views 6

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Continue Reading
OCI Energy and Arava Power Ignite SunRoper Solar Project

Updated Category News Views 3

Bridging Houston's Energy Gap with New Solar Power There's a new player in town aiming to meet the growing electricity demand in the Houston area. On September 1, 2026, OCI Energy and Arava Power, along with their project partners, broke ground on the SunRoper Solar project in Wharton County, Texas. This isn't just any solar venture; it's a hefty 347 MWdc facility that's...

Continue Reading
TaxRock's New Platform Takes on IRS Complexity

Updated Category News Views 6

An AI Solution Tackles IRS Complexity Right out of the gates, TaxRock is shaking things up in the tax world with its latest rollout. While the word 'IRS' rarely sparks a grin, the California company aims to change the way folks handle their tax data. Their new consumer platform promises to lace taxpayers' frazzled nerves with the calm structure of AI. Let's face it—most...

Continue Reading
BNI Sets Sights on Big Expansion Across Europe

Updated Category News Views 4

BNI Charges Forward: Europe Expansion Strategy This one's got me thinking about how networking giants like BNI are not sitting back comfortably, they're on the move. BNI is going all-in on Europe, making serious waves by locking down new franchise territories in France, Italy, and the UK. It's no small feat—they already have a footprint there with over 35,000 members...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 2

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading
Father's Bone Marrow Gift Transforms Daughter's Future

Updated Category News Views 1

When Hope Hinges on a Medical Miracle In a world of high-stakes trades and volatile markets, you'd think that there isn't room for stories like this. But life throws curveballs, some more daunting than what you'll find on Wall Street. Take the case of Victoria, a toddler who beat the odds thanks to a groundbreaking bone marrow transplant at Nicklaus Children's Hospital in...

Continue Reading
TDS Kills Array Merger, Revives Stock Buyback Plans

Updated Category News Views 7

Shifting Gears: TDS Drops Array Deal There's always something brewing in the halls of corporate mergers. Just when you thought Telephone and Data Systems, Inc. (TDS) was about to cinch a deal with Array Digital Infrastructure, Inc. (NYSE: AD), they've turned the car around. TDS decided it won't be going ahead with its acquisition of the remaining shares it doesn't already...

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 8

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Aitan Raises $41M to Expand Robotic Warfare Tech

Updated Category News Views 5

Pioneering Sovereign Robotic Warfare The defense sector's landscape is shifting, and Aitan is driving a movement with their 'Robotic Sovereignty-as-a-Service'. Coming out of stealth with a hefty $41 million funding boost, this Israeli-American company is redefining modern warfare's playbook. In today's unpredictable world, traditional combat methods are becoming relics of...

Continue Reading

Top 5 Most Recently Viewed Articles

Digital Personalization: The New Intelligence Frontier

Updated Category News Views 1

A Surprising Twist in the Digital Tale If you think the digital age's personalized touch is just about remembering your shopping habits, you're in for a shock. Shadow Sciences Group out of Edina, Minnesota, blew the lid open with their series, 'The Weaponization of Personalization.' While we all adore a platform predicting our next buy, turns out, we're dabbling in a...

Continue Reading
1911 Gold Charts Aggressive Growth Path for 2025 and Beyond

Updated Category News Views 201

1911 Gold Charts Ambitious Growth Path for 2025 1911 Gold Corporation (TSXV: AUMB) has reflected on its accomplishments in 2024 and presented an exciting growth strategy for 2025, specifically targeting the True North gold project and the surrounding Rice Lake property. With a focus on expansion, the Company aims to maximize the potential of its holdings in Manitoba. Key...

Continue Reading
Join Commercial Metals for Their First Quarter Earnings Call

Updated Category News Views 120

Join Commercial Metals for Their First Quarter Earnings Call Commercial Metals Company (NYSE: CMC) is eager to invite you to their upcoming conference call. This event, marking the company's first quarter earnings release for fiscal 2025, is scheduled for January 6, 2025, at 11:00 a.m. Eastern Time. You can listen to the insights shared by Peter Matt, the President and...

Continue Reading
Transforming $1000 into $29,762: The Arista Network Journey

Updated Category News Views 125

Investing in Arista Networks: A Decade of Growth Arista Networks (NYSE: ANET) stands as a remarkable example of financial success over the past ten years. This tech company has not just participated in the market but has outperformed it by a staggering 27.58% annually, boasting an impressive average annual return of 40.26%. As of now, Arista Networks holds a market...

Continue Reading
Top Stock Performers Already Gaining Momentum in January

Updated Category News Views 360

January Sees Significant Stock Market Gains The new year has commenced with enthusiastic support from stock market investors, as the S&P 500 index has rallied impressively, marking a month-to-date increase of 3.7%. This surge is largely attributed to an outstanding earnings season that is expected to break records, with nearly 85% of the early S&P 500 reporters surpassing...

Continue Reading